Cambium Bio Limited has released a press release.
Appendix 4E
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4e-190
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Restructuring results in 50% reduction in operating costs
- Updated Investor Presentation
- Offer Booklet
- Investor Presentation
- Successful Private Placement
Later from Cambium Bio
- Regeneus receives A$1.5 million in R&D Tax Incentives
- Japanese Biotech Fund takes up all Rights Issue Shortfall
- Chairmans Address to Shareholders
- CEO Presentation to 2019 Annual General Meeting
- AGC Agreement termination paves way for commercial partner
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio